Search Login Register

simendan (Levosimendan) Summary

Description: a troponin modifier, a phosphodiesterase III inhibitor, and an inhibitor of voltage-sensitive Ca(2+) current; structure given in second source

Also Known As: Levosimendan; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; Abbott brand of Levosimendan; OR 1259; OR-1259 Show All >>

Networked: 659 relevant articles (126 outcomes, 165 trials/studies) for this Bio-Agent

Key Diseases for which simendan is Relevant

  1. Heart Failure : 58 outcomes 89 studies in 364 results
  2. Myocardial Infarction : 13 outcomes 11 studies in 44 results
  3. Cardiogenic Shock : 13 outcomes 9 studies in 47 results
  4. Ischemia : 7 outcomes 9 studies in 33 results
  5. Low Cardiac Output : 7 outcomes 7 studies in 36 results
Show All >>

Drugs Related to simendan

  1. Dobutamine
  2. Calcium
  3. simendan (Levosimendan)
  4. Adenosine Triphosphate (ATP)
  5. Carbon Monoxide
  6. Norepinephrine (Noradrenaline)
  7. Dopamine (Intropin)
  8. N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)
  9. Interleukin-6 (Interleukin 6)
  10. Oxygen
Show All >>

Therapies Related to simendan

  1. Cardiopulmonary Bypass (Heart-Lung Bypass)
  2. Cardiopulmonary Resuscitation (CPR)
  3. Intravenous Infusions
  4. Ligation
  5. Artificial Respiration (Mechanical Ventilation)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.